Lilly, company dedicated to medicine with 147 years of experience in research and development of innovative medicines for health care and world leader in the treatment of diabetes has obtained approval from the Federal Commission for the Protection against Health Risks (COFEPRIS) for the use of tirzepatide in Mexico for patients with type 2 diabetes.
The safety and efficacy of Tirzepatide are supported by the global, multicenter phase 3 clinical development program called SURPASS, which began at the end of 2018 and in which Mexico contributed 15% of the total number of patients.
The unique mechanism of action of this molecule contributes to modifying the course of the disease by increasing insulin production and reducing the level of glucose in the body – among other things -, thus improving the clinical outcomes of patients. These types of medications, like all Lilly solutions, must always be prescribed by a doctor in the indications approved by the health authority, making appropriate use of them, putting the safety and quality of life of patients at the center.
“The SURPASS-2 clinical study showed that tirzepatide offers superior results compared to its comparator. With about 9 out of 10 patients achieving blood glucose control goals (the Dr. Juan Pablo Ramírez, medical director of the diabetes area at Lilly.
With this approval, the horizons for the treatment of the 14.6 million adults living with this disease in Mexico are expanded, according to the most recent data from the National Health and Nutrition Survey (ENSANUT 2022). Furthermore, it marks the introduction of a new therapeutic class to address the serious public health problem currently facing the country.
“At Lilly, we are fully committed to employing all necessary resources and efforts to accelerate the arrival and distribution of Tirzepatide in Mexico, aware of the serious public health problem that diabetes represents in the country. Currently the medication is not available in Mexico. “We will appropriately and timely inform the medical community about availability.”commented Karla Alcázar Uribe, president and general director for Lilly Latin America.
The company is concerned about the growing proliferation of counterfeit products that are advertised or designed to look like its genuine medicines. Lilly is the only legal supplier of these medications and does not supply the active ingredient to compounding pharmacies, medical spas, wellness centers, online retailers or other manufacturers.
Therefore, products that imitate or suggest to be identical to Lilly treatments and that are sold and distributed in Mexico put the health of people who consume these products of unknown origin at risk.
For Eli Lilly and Company of Mexico, safeguarding the health of patients against the risks associated with counterfeit products will always be a priority. The company is committed to ensuring that patients only receive innovative, safe and effective medicines, approved by the country’s regulatory bodies, such as COFEPRIS. In this way, it guarantees that these products reach those who need them through authorized channels and legally, thus protecting patients.
**Based on the discussion of the SURPASS clinical trial, what specific challenges faced by Mexican patients with type 2 diabetes did Lilly aim to address with tirzepatide?**
## Interview: A New Hope in the Fight Against Diabetes in Mexico
**Introduction:**
Welcome to World Today News. Today we have the privilege of discussing a groundbreaking development in the fight against type 2 diabetes in Mexico. Joining us are Dr. Juan Pablo Ramírez, Medical Director of the Diabetes area at Lilly, and Karla Alcázar Uribe, President and General Director for Lilly Latin America.
**Part 1: Understanding the Breakthrough**
**(Host):** Dr. Ramírez, the approval of tirzepatide by COFEPRIS is a significant advancement. Could you explain the unique mechanism of action of this drug and how it differentiates itself from existing treatments for type 2 diabetes?
**(Dr. Ramírez):**
**(Host):** This SURPASS clinical trial involved a notable contribution from Mexican patients. Ms. Alcázar, what was the rationale behind Lilly’s decision to conduct a large portion of the trial in Mexico?
**(Ms. Alcázar):**
**(Host):** Dr. Ramírez, the study results show impressive efficacy in achieving blood sugar control goals. Can you elaborate on the impact this could have on the daily lives of people living with type 2 diabetes?
**(Dr. Ramírez):**
**Part 2: Access and Availability**
**(Host):** Ms. Alcázar, the prevalence of type 2 diabetes in Mexico is alarming. How does Lilly plan to ensure widespread access to tirzepatide once it becomes available?
**(Ms. Alcázar):**
**(Host):** The article mentions the importance of doctor prescription and appropriate use. Could you both elaborate on the potential risks associated with misuse or self-medication with this drug?
**(Dr. Ramírez and Ms. Alcázar):**
**(Host):** Lilly has also raised concerns about counterfeit versions of its medications. What measures are in place to protect patients from these potentially harmful imitations?
**(Ms. Alcázar):**
**Part 3: Hope for the Future**
**(Host):** This approval marks a significant step forward in tackling diabetes in Mexico. Looking ahead, what are your hopes for the impact of tirzepatide on the lives of patients and the healthcare system as a whole?
**(Dr. Ramírez):**
**(Host):** Ms. Alcázar, Lilly’s commitment to innovation is evident. What other initiatives are underway within Lilly to address the growing challenges of chronic diseases like diabetes in Latin America?
**(Ms. Alcázar):**
**Conclusion:**
(Host): Thank you both for sharing your insights and expertise. We at World Today News believe this approval represents a ray of hope for millions of Mexicans living with type 2 diabetes.
Thank you for joining us on World Today News.
